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ABSTRACT
In 1928, the profound effects of penicillin were discovered and antibiotic treatments
became extremely popular. Broad-spectrum antibiotics, like tetracyclines, have been
since branded as cure-all prescriptions and used profusely in the Western World and
abroad. Due to ignorance of specific biochemical mechanisms and the misuse of
antibiotics these drugs inadvertently allowed the rise in prevalence of antibiotic resistant
strains of certain bacteria as the century progressed. Now, the specific genetic causes and
mechanisms of antibiotic resistance are being understood, but the fight against
antimicrobial resistance is far from over. In the United States, thousands of fatalities are
caused annually by infections of this variety. In impoverished nations, the reality is
dimmer and antibiotic resistance demands research and funding so that lives can be
saved.
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Antibiotics, when used properly, have been one of the largest lifesavers humanity
has ever had. But when used improperly, they can have a converse effect. In most
developed countries, antibiotics have revolutionized the way conditions are treated. In
just the first half of the last century, many people would lose their lives to tuberculosis,
pneumonia and other common bacterial infections. Vaccines have worked to curb their
incidence and antibiotics have been used to cure infected patients. However, increasing
use of antibiotics has given way to bacteria that are resistant to many common forms of
antibiotics. These antibiotic resistant strains now work to cause harm to thousands or
hundreds of thousands of people.

ANTIBIOTICS AND THE CAUSE OF RESISTANCE
Even though antibiotics have successfully subdued many infectious agents, there
are a few other infectious agents that continue to be problematic in countries like the
United States and plague impoverished parts of the world. Before specific bacterial
agents for disease are analyzed, however, it is proper to first discuss the contributing
factors that produce resistant strains and allow curable infections to persist. Then, it
should be determined how these problems are amplified in areas of the world that are
remote, impoverished or subject to the high stresses from the environment, wars or other
external factors. Then, solutions can be proposed.
Bacteria are single-celled organisms that live almost everywhere and provide a
wide range of functions. They are diverse and normally not harmful. Many bacteria live
in the human GI tract, contributing to normal digestion. Other bacteria may live
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commensally on human skin. For example, certain kinds of bacteria living on skin
consume the chemical compounds in perspiration. As a byproduct, body odor is produced
by these bacteria, but they do not harm their host [17]. Bacteria that live non-parasitically
on or in a person are said to be a part of that person’s normal flora. Essentially, bacteria
are widely diverse, inhabiting a variety of environments and able to adapt and survive in
many different situations.
Some bacteria do inflict disease upon their host. Common infectious bacteria
include various strains of Escherichia coli, Staphylococcus aureus and Salmonella. It
should be noted that these microbes (and many others) may not cause symptoms of
infection in a person unless they are present in significant amounts; a small amount of
these bacteria may be a part of the normal flora. The common treatment for many
bacterial infections is the use of a prescribed antibiotic. An antibiotic is a drug that acts to
target bacteria with one or more specific features. There are four general classes of
targets, called mechanisms of action, the antibiotic will utilize. These are targeting the
cell bacterial wall, inhibiting protein biosynthesis, inhibiting DNA replication, and
inhibiting folic acid synthesis [17]. So, a certain antibiotic may utilize one or more of
these mechanisms of action to the detriment of bacteria at certain stages of growth and
development.
For example, the antibiotics in the group oxazolidinones act to inhibit both the 50s
and 70s subunits of the prokaryotic ribosome and therefore prevent protein biosynthesis.
Quinilones, however, act to prevent DNA gyrase from producing and relieving supercoils
during DNA replication [17]. The bacteria cannot replicate and die. The degree of
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specificity for an antibiotic drug and its target bacteria varies widely. If the antibiotic can
be used to treat both gram-positive and gram-negative bacteria it is called broad-spectum,
as it is capable of effective treatment over a diverse group of infectious agents. Good
examples of these are tetracycline, chloramphenicol and carbapenems. Narrow-spectrum
antibiotics are those that are effective against a selective range of bacteria that is either
gram-positive or gram-negative [25]. These are generally employed when the diagnosis is
clear or antibiotic testing has been done to pinpoint the causative agent or when it is
feared a more broad-spectrum treatment would harm normal flora. Additionally,
physicians often prescribe antibiotics in tandem to amplify their effectiveness against a
bacterial infection, a response called synergy. This way antibiotics with different
mechanisms of action can work together to defeat an infection. This will generally
shorten the illness and lessen damage to the patient.
Even with the largely beneficial properties of antibiotics, their overuse and misuse
contributes to problems of destroying normal flora and the allowing of antibiotic
resistance. Antibiotic resistance is simply the ability of certain strains of bacteria to be
less affected by an antibiotic that would normally be effective against that kind of
bacteria. It is important to clarify that there are degrees of resistance due to genetic
variance and that the extent that a strain may be resistant may or may not be significant.
Certain causative agents come into play in the development of this phenomena but the
basis of resistance in bacteria is genetic. Bacteria, even within the same species, can have
huge variations in their phenotypic expressions. Mutations as well as extra genes received
in conjugation may allow the expression of these unique characteristics in a small portion
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of a bacterial colony [17]. These mutations or genetic variations are generally not for
avoiding antibiotics, but instead may harm the ability of the cell to grow and multiply and
therefore be selected against under normal conditions. However, when the bacterial
colony is being attacked by an antibiotic treatment, these useless or even harmful
expressions may prove themselves to be useful mechanisms of resistance and be used to
inactivate the antibiotic or reduce concentrations of it from the cell.
An example of one of these mechanisms is the employment of efflux pumps to
force antibiotics out of the interior of the infectious prokaryote. In this way, certain
strains may prevent treatment concentrations from rising to dangerous levels. Other
resistant bacteria may alternate confirmations of the antibiotic’s target molecule,
essentially inactivating the treatment, such as modifying penicillin binding proteins on
certain penicillin-resistant strains’ cell walls [17]. There are many other mechanisms by
which bacteria can accomplish these feats and persist through the course of a treatment.
However, antibiotic resistant infections do not always arise because a person is colonized
and subsequently infected by an already resistant strain. On the contrary, it is often that
most of a target colony is sensitive to the treatment, but the strains allowed to persist may
then grow and compose a larger percentage of the population that causes a second
infection.
A theoretical example could be a person who is not feeling well and sees a
physician for treatment. The person presents to the doctor with a sore throat and is
diagnosed with strep throat, caused by Streptococcus pyogenes. As this is a common
ailment, the doctor prescribes the normal treatment of a penicillin-derivative and sends
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the patient home to recuperate. The 10-day antibiotic regimen is followed for the next six
days, and the patient, feeling fully better decides to forgo the remaining days of treatment
and save some left-over antibiotic in case of a future emergency or another bout with
strep. However, the person soon is not feeling well again and, realizing the infection has
returned starts to self-administer the remaining antibiotic to no avail.
In this scenario, the patient has taken the antibiotic long enough to become
asymptomatic, but not long enough to be cured. Furthermore, while the original colony of
bacteria was made up of nearly all penicillin-sensitive bacteria, as evidenced by the
patient feeling better, the recurrence of infection may feature a colony that has had its
population shifted so that the small number of penicillin-resistant bacteria could persist
and make up a much larger portion of the next infectious colony. This ultimately
rendered the second round of treatment ineffective and could have been prevented if the
patient had completed all 10-days and adequately killed all the sensitive bacteria. This
would leave the resistant bacteria at a level too low to cause infection.
Another hypothetical scenario for the rise of a resistant infection would be that of
a mistaken identity. The goal of healthcare in any setting is two-fold; it is to provide
quality services that sufficiently serve the quantity of patients. Therefore, if a patient
presents to the hospital with symptoms of pneumonia, or strep throat or any number of
common illnesses, it is normally the most efficient thing to do to prescribe the common
antibiotic used for treating the diagnosis. This saves the patient money and the hospital a
room and hours spent working to test each infection for positive identification. If each
person who came into a hospital with a bacterial infection had to be swabbed, their
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sample colonized, identified and sensitivity tested, hospitals would have a much larger
workload. Also, the time it would take to test each sample would cause patients to have a
persisting infection for two-three days until the diagnosis was confirmed. That is why
antibiotics are generally prescribed based on presenting symptoms.
While the majority of cases will respond normally to the antibiotic, a small
percentage of patients will maintain their symptoms. In these cases, the physician may
prescribe other antibiotics as a sort of guesswork or test the bacteria in the patient for its
sensitivity against these other antibiotics. Both are trial and error approaches and take
time. It is not uncommon for a patient to endure weeks of hospital visits and leave with a
large bill for an infection that at first seemed routine. In cases of patients with
compromised immune systems, the weeks on end of infection may lead to permanent
damage or even death.
It should be noted that no strain of bacteria is resistant to all treatments. Just as no
antibiotic is truly a “cure-all” no “superbug”, as some are commonly called, is resistant to
every mechanism of action. Infections may be hard to treat efficiently or find the
antibiotic to best inactivate them, but this is no reason to declare a resistant colony
incurable. The rest of this thesis will aim to summarize some of the biggest threats to
people and how current research is attempting to quell these threats. With proper research
and hospital techniques, the rate of hospital acquired and community acquired resistant
bacterial infections can and will decrease, especially in underserved and impoverished
communities.
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TESTING: TIME AND COST
The most common way that resistant strains are tested for sensitivity to other
antibiotics is via the Kirby-Bauer method. In this method, the suspect bacteria are plated
on Mueller-Hinton agar and incubated for 24-28 hours. Disks containing certain
antibiotics are put on the plates and the diameter of nongrowth around each disk, termed
the “zone of inhibition”, is measured [27]. The zone of inhibition is roughly circular is
produced when the bacteria around the antibiotic have been either killed or prevented
from growing. The larger the diameter of the zone indicates that a low concentration of a
certain antibiotic has diffused through the agar to inhibit a relatively large amount of
bacteria. In this way, the disk diffusion test provides an easily observable and
quantifiable test for antibiotic susceptibility. It is also relatively inexpensive to perform,
making this the standard test for determining the most efficient antibiotic or antibiotics to
use in treatment.
Another common procedure utilizes broth; well plates are inoculated with the
bacteria causing the ailment and treated with serial dilutions of various antibiotics. This
test is slightly more expensive, about $15, but allows for the testing of the antibiotics at
differing concentrations [27]. Testing for effectiveness at varying concentrations is
important because it helps healthcare professionals to prescribe the minimum
concentration of antibiotic to treat with the maximum effectiveness and the smallest
damage possible to normal flora in the vicinity of the infection. These factors cause broth
microdilutions to be popular tests.
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Other procedures include automated tests. The major advantage of automated
instruments is the short time in which samples can be processed and results read.
Siemens’ MicroScan Walk Away, one of four FDA approved instruments of this class,
can read and analyze numerous samples tested against different antibiotics in as little as
3.5 hours for gram-negative bacteria. For gram-positive or mixed samples, it can be
accomplished in a minimum of 4.5 hours. The MicroScan Walk Away, like its
counterparts, uses fluorescence reading to sense optical signals and detect reactions
between an antibiotic and bacteria at much lower concentrations and much earlier stages
than a manual culturing test [27]. This allows these machines to process every sample in
under 24 hours, as opposed to about 72 hours for other testing methods. Yet, while the
turnaround time is impressive, a quick online search will reveal price points for the
MicroScan Walk Away falling between $12,000 and $15,000, making it effectively a
non-option in many healthcare settings around the world. The challenge of healthcare,
especially in areas with common antimicrobial resistant infections, is that finances must
be used efficiently so that the best quality care can be given to the majority of patients.

SPECIFIC THREATS
Hospital-Acquired Infections
Hospital-acquired infections (HAI), also called nosocomial infections, are as the
name indicates, infections that are contracted while a patient is at a healthcare facility.
According to the Centers for Disease Control and Prevention (CDC), the United States
has nearly 2 million infections of this variety causing 99,000 deaths annually. The two
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major types are urinary tract infections (UTI) and surgical site infections (SSI) [12, 18]. If
HAIs were considered their own category, they would rank sixth on a list of the top ten
causes of death in the United States, just after strokes. Yet, since HAIs cover a broad
variety of ailments, they often allude the public eye. Some HAIs cannot be prevented,
regardless of how well the team of healthcare workers performs their duties. However,
there are many instances where they are preventable. Sadly, patients still contract these
infections, spend extra time in the hospital, and even pass away from them. This risk of
fatality is amplified if the bacteria causing the infection presents itself with antimicrobial
resistance. An understanding and a healthy fear of HAIs and antibacterial resistance in
this context will undoubtedly save thousands of lives in the coming years.
While studying the nature of HAIs may not be quite as appealing as studying
topics such as Alzheimer’s disease, cancer or autism, the studies that have been done do
show practices that can contribute to lowering of the risk of contracting infections. For
example, studies found that MRSA infections in an American intensive care unit
decreased by 25% when chlorhexidine was used for handwashing [11]. However, though
preventative measures exist to stop the spread of HAIs caused by causative agents such as
MRSA, HAI frequency will likely increase. This is due to the increasing intricacies of
healthcare services [21]. Hospitals now have extensive therapies for patients with
preexisting conditions such as diabetes, AIDs and other immunosuppressant diseases.
These people already possess an increased risk of hosting bacterial infections and in the
confines of a hospital the risk is often amplified. Therefore, despite proper hygiene, as
medical care evolves to treat more immunodeficient patients, HAIs will continue to
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plague patients unless proper prophylactic treatments are discovered. Antibiotic
resistance will only exacerbate this issue.

Community-Acquired Infections
Community-acquired infections (CAI) are those infections that are transferred
from the environment or other people. When it comes to acquiring infections that are
resistant to antibiotics, the location plays a large role. Certain infections are more
common in specific parts of the world. Tuberculosis and pneumonia are both diseases
that are often CAIs and can be found in higher prevalence in places such as Russia and
parts of Asia [15, 24]. E. coli infections are common in environments where the cleaning
and preparation of food is less strictly regulated [10]. Generally, impoverished locales
drive many CAIs.
But not all CAIs are infections like E. coli, which would cause American
restaurants to shut down, or tuberculosis that would be a shocking diagnosis to a person
who has not left the West. Methicillin-resistant Staphylococcus aureus (MRSA) is an
example of a seriously threatening disease causative agent that can be spread as an HAI
or via the community. Since it can be carried quietly and asymptomatically, MRSA can
be spread person to person until an injury or otherwise immunocompromising procedure
allows it to act and harm its host. Particular events are very conducive to the spread of
MRSA and infectious agents like it. Wrestling, for example, has been shown to help
MRSA spread from the skin of one person to another much more easily, as has been
shown in American schools [3]. In many developing countries where the percentage of
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the population that carries MRSA or similar bacteria is much higher similar
circumstances will assuredly lead to higher transmission rates. The subsequent portion of
this thesis will be dedicated to analyzing antibiotic resistant infections that pose a
particularly serious threat to impoverished peoples.

Methicillin-Resistant Staphylococcus Aureus
Methicillin-resistant Staphylococcus aureus (MRSA) has been kindly nicknamed
a “super bug”. This is because it is resistant to common antibiotics such as penicillin,
oxacillin, methicillin and amoxicillin, and spread merely by contact. MRSA is the poster
child for antibiotic resistance and, per the CDC, 2% of the population carries MRSA
while 33% carry normal S. aureus. However, in developing countries, MRSA is
overrepresented. One study has determined that around 50% of Egypt, Jordan and
Cyprus’ Staph carriers have MRSA [5]. The implications of this increase in prevalence
are far-reaching. Hospitals that are often overwhelmed and underfunded, especially amid
a refugee crisis, must battle to treat MRSA infections with unconventional antibiotics.
Furthermore, because people from countries like Jordan, Egypt and the rest of the Middle
East are emigrating all over the world, they are carrying a higher prevalence of MRSA
with them. Going unchecked and unfought, the battle against MRSA could get much
worse.
The current state of MRSA infections in the West is bettering. Multiple studies
have indicated that cases and fatalities from invasive HA-MRSA infections in the United
States have decreased by around 50% from the end of the 20th century to the beginning of
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this decade [6, 36]. Yet, the threat is still very real and MRSA causes 80,000 infections
and over 11,000 deaths annually in the United States [36]. Until there are no deaths from
MRSA, the severity of MRSA infections in the West cannot be understated. Since the
situation in the West, it is no surprise that in developing nations without the proper
resources for adequate preventative methods the outlook would be even more concerning.
Close quarters, poor sanitation, and lack of hygiene education and cleaning supplies all
contribute to a worsening situation in these countries. In addition, generally impoverished
countries like India, Algeria and countries in Central and South America have higher use
of broad-spectrum antibiotics per the Center for Disease Dynamics Economics and Policy
[37]. This same source indicates that many of these countries have high prevalence of
MRSA. In India, where high amounts of broad-spectrum antibiotics are prescribed, 47%
of the Staph aureus strains are considered to be MRSA. Venezuela has a 60% makeup of
MRSA strains and a high prescription rate of broad-spectrum antibiotics [37]. There is a
clear correlation between the prescription of broad-spectrum antimicrobial medications
and the high incidence of MRSA and infectious agents like it.

Clostridium difficile
Clostridium difficile infections (CDIs) are caused gram-positive bacilli and are the
number one hospital-acquired pathogen. They are also a serious threat in the realm of
antibiotic resistance. In 94% of cases these infections are nosocomial, and patients
undergoing antibiotic treatments possess an increased risk [1]. C. difficile is an
opportunistic infection, meaning that it will not pose any serious threat to a person with a
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healthy immune system and likely is already inhabiting their gut. However, if a person is
immunocompromised they may be susceptible to infections by C. difficile causing
diarrhea and bloating. Becoming immunocompromised may be the result of a preexisting
condition (e.g. AIDS or a previous infection) or having significant portions of normal
flora being wiped out by antibiotics. If the infection progresses and bacteria spills into the
abdominal cavity, death can result.
The CDC reports that C. difficile is responsible for 250,000 infections and 14,000
deaths each year in the United States, which is four times higher than the rate ten years
ago. Additionally, it is the cause of a financial burden of over 1 billion dollars annually in
preventable costs [36]. Many C. difficile infections are unavoidable, because a person’s
immune system may be repressed out of necessity for treating a different infection with
antibiotics that affect normal flora makeup. Then, provided the opportunity to grow, C.
difficile will colonize the intestine and begin causing characteristic symptoms [4].
However, many infections can be prevented with proper healthcare techniques and
antibiotic use. For example, treatments like colistin are used against specific grampositive and almost all gram-negative infectious agents, making it a versatile broadspectrum antibiotic. However, a byproduct of being so effective against such diverse
harmful bacteria means that colistin also inhibits many species of microbiota that
compose the normal flora. C. difficile is unaffected by colistin-like drugs and therefore is
permitted to grow and become infectious [30]. The use of pathogen-specific narrowspectrum antibiotics as determined by sensitivity testing could be helpful in preventing
cases of C. difficile that arise by this pathway.
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Once contracted, C. difficile is hard to treat because of inherent resistance to
common broad and narrow-spectrum antibiotics such as cephalosporins, penicillins,
carbapenems, aminoglycosides, and fluoroquinolones [13]. Additionally, effective
treatments against gram-negative bacilli are sparse or may further damage the natural
microbiota of a person. The need for an effective treatment is evident in the United
States: there has not been a new antibiotic approved to treat CDIs in the last over twenty
years [13]. Continuous treatment of C. difficile with broad-spectrum antibiotics, like
vancomycin, is not a long-term solution as resistance to these may soon arise.
As is the case with many other antibiotic resistant pathogens, the havoc wreaked
in low-income countries is hard to quantify because of a lack of studies and data.
However, some studies have indicated that the reality is grim when it comes to CDIs
contracted in the developing world. One study analyzed over 800 Swedes who were
suffering from diarrhea. C. difficile was found to be the second largest pathogenic cause
of the symptoms in the study and the majority of CDIs were found in participants who
had recently traveled to low and middle-income countries [35]. While it is fallacious to
assume that correlation is equivalent to causation, there are other indications that the part
of the world that is less wealthy is subject to harsher effects of CDIs and antibiotic
resistant strains.
Although generally not as precise as the studies conducted in the Western world,
studies from Africa, Central America and developing Asia have shown that CDIs may be
occurring at more alarming rates than in places like the United States [23]. Furthermore,
these studies show that it is not only normal C. difficile causing the infections, but also
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antibiotic resistant strains. One study in Peru identified and observed specific mutations
in their replicating processes that conferred varying degrees of antibiotic resistance just
like mutations that were observed in the bacteria that caused an outbreak in Quebec in
2004 that claimed the lives of over 1,000 people [23]. It makes sense though, that
developing countries should show increased prevalence of C. difficile and exhibit
resistant strains because of many factors. These factors generally boil down to two
aspects; general hygiene and antibiotic use.
Whether it is because of a lack of supplies, inadequate health training or a myriad
of other factors that change from nation to nation, low-income parts of the world
generally do not exhibit the same standards of hygiene and sanitation as do the higher
income parts of the world, especially in healthcare settings. Hospitals and health centers
in war torn and poverty stricken areas are shown to less often use gowns and gloves while
treating patients [23]. This makes it much easier for the passage of spores and infectious
agents to occur. Increasingly unregulated use of broad-spectrum antibiotics, as opposed
to regimented narrow-spectrum ones in certain situations, increases the probability of
resistant strains to arise as well. Spore-killing cleaning supplies like bleach are not as
readily available for household cleaning and, therefore, infections may spread quickly
through whole villages. Statistics may not be available on the prevalence of antibiotic
resistant strains or the numbers of deaths caused by them, but the developing world may
very well be on the verge of an epidemic. Just as with other infectious agents, the key to
preventing thousands of deaths each year by CDIs lies mainly in prevention. If the
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number of cases of C. difficile can be reduced, so too then will the number of resultant
deaths.

APPLICATION
Comparing MRSA prevalence and antibiotic usage around the world
Thus far this work has dealt with healthcare in rural and underserved settings in
broad examples. Before closing it is appropriate to discuss a specific application of
antibiotic usage and correlating issues of resistance. Three nations have been chosen to
represent different demographics, and the rates of MRSA prevalence were compared with
their general uses of antibiotics. The United States was chosen as a representative country
of certain developed nations that have access to medical technologies that
underdeveloped nations do not normally have, and prescribe large quantities of broadspectrum antibiotics. Sweden has been chosen as a second representative country of the
West as it has some of the lowest prescription rates of broad-spectrum antibiotics while
simultaneously having some of the highest rates of narrow-spectrum antibiotic use.
In contrast to both countries, Syria has been studied as a country that has with a
damage and overwhelmed healthcare system as a result of a civil war and political
turmoil in recent years. The healthcare system in Syria is overwhelmed and
undersupplied resulting in a higher proportion of treatments with broad-spectrum
antibiotics. Syria has also been studied for two other important reasons, namely, that
there is more data on Syria’s healthcare than many other nations in similar circumstances
and that the current political climate has caused a massive influx of refugees into
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European countries, especially Sweden, providing a brand-new field of research. In
studying these representative nations patterns should be evident between practices and
prevalence of MRSA in the different populations. MRSA has been used as a
representative pathogen because there is clearer data in regards to MRSA prevalence and
sources than many other bacterial agents. Data on antibiotic use and prevalence has
largely been obtained by the CDDEP, which synthesizes data from the CDC and
equivalent organizations around the world.
The colonization rate of MRSA in the United States and Sweden is very similar,
with most estimates placing it between 2-4% [37]. It is important to recognize that
colonization rates are not the rate at which a population suffers from an infection, but
rather what proportion of the population carries a specific agent, infectiously or noninfectiously. Syria’s rate is much higher, 15-20%, and is descriptive of many countries
with less access to proper sanitation and healthcare [26]. But the statistics become
shocking when rates of infections are compared. There is no accurate data indicating rates
of MRSA infections in Syria or its surrounding countries, but since there is a high rate of
colonization, the incidence is assumed to be high. Sweden, conversely, has a very low
prevalence for MRSA sitting at 0.3 infections per 10,000 people. Being that both the
United States and Sweden are developed, well off countries with similar rates of
colonization, one would expect the prevalence to be similar in the USA. But, the USA
holds a rate of 2.6 cases per 10,000, roughly eight times the rate of Sweden [20]. Death
rates are hard to determine due to simultaneous infections, but they tell a similar story.
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How can two similar nations like Sweden and the USA present such drastically
different rates of infection? It seems that the problem resides in the methods of treating
bacterial infections that each nation employs. Per the CDDEP, Sweden prescribes 588
standard units of fluoroquinolones per 1,000 people in its population. The United States
prescribes 1,430 standard units per 1,000, which puts the USA in the company of Egypt,
Jordan, India and Brazil for similar rates; all of which are countries with overwhelmed
healthcare systems [37]. The story is the same across the board for broad-spectrum
prescriptions. The United States issues broad-spectrum penicillin derivatives (ampicillin,
amoxicillin, carbenicillin and the like) at eight times the rate that Sweden does, adjusted
for population [37]. Recall that MRSA, like C. difficile and many others, may colonize a
person without causing any noticeable harm. It is when these infectious agents are
permitted to grow beyond their normal capacities that a person becomes infected. Broadspectrum antibiotics kill wide swaths of “good” and “bad” bacteria indiscriminately, and
therefore, can be detrimental to normal flora. It should be expected then to see a
correlation between high broad-spectrum prescription rates and high MRSA prevalence.
For a country like the United States, the key to defeating a pathogen like MRSA
may be in taking cues from nations like Sweden. Not only does Sweden prescribe less
broad-spectrums, they also issue higher rates of narrow-spectrum antibiotics. Sweden
prescribes normal penicillin (effective against only gram-positive bacteria) and its
narrow-spectrum derivatives at nearly ten times the rate that the USA does [37]. This
implies that Swedes test for a pathogen’s susceptibility to antibiotics more often than
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their American counterparts. Perhaps imitating this practice can help reduce the burden,
costs and harm caused by MRSA in the USA.
Sadly, the MRSA problem in Syria and many other countries is not easily solved.
Infection and death rates may drop with more people willing to give of time and money
to help Syrians and other impoverished and underserved peoples get the screening and
treatment they require. However, if war, famine and poverty exist in a population,
antibiotic resistance will surely be a plague to that group.
But the issue remains on what practices need to be employed so that countries like
Sweden, who accept massive amounts of Syrians and other refugees, can keep rates of
MRSA infections low. Sweden already has a shortage of doctors and cannot afford to
have antibiotic resistant infections overrun the healthcare system. One possible solution
may be the employment of a system for screening populations of people with higher risks
of MRSA and prophylactically treating them. This system has been modeled by the
Dutch, who have notoriously low rates of antibiotic resistant infections but also large
refugee populations [26].
Per a recent study, the Dutch method, termed “Search and Destroy”, has greatly
reduced costs associated with MRSA infections and prevented deaths. The method
involves screening people who are members of groups with a high prevalence of MRSA
(e.g. Syrian refugees) and preemptively isolating those who have tested positive. Those
isolated receive prophylactic antibiotics and had their colonies repeatedly examined until
they were considered uncontaminated [33]. The study concluded that the Search and
Destroy method is cost and labor beneficial when used in populations with a prevalence
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of 17% or greater [33]. Countries like Sweden may greatly benefit from employing a
technique for screening, testing and prophylactically treating MRSA. Even the United
States should be able to employ a similar strategy in its widely varied population to help
cut down on healthcare costs, patient costs and death rates.

IMPORTANCE
So then, what is the reason for writing a thesis on the grim realities of antibiotic
resistance and the tragedies they cause in developed and impoverished places? The first
reason is to bring light to the issue. Antibiotic resistance, minus the misguided use of
terms like “superbug”, lacks the luster that other medical areas of interest has. Yet, the
need for solutions is growing larger each day. A refugee crisis has driven large swaths of
Middle Easterners and North Africans into Europe. Waves of immigrants have moved
from Mexico to the US. The prevalence of certain bacterial infections and resistant strains
will soon no longer be sequestered in the less developed parts of the world. MRSA, C.
difficile and many others are being unnoticeably transferred over borders. To improve
healthcare and end the suffering of these migrating peoples, the proper preventative
measures and antibiotic resistance testing methods need to be commonplace in western
hospitals.
However, just because the threat of antibiotic resistant infections is spreading
does not mean that the threat in impoverished areas is going away. The other significant
goal of this thesis is to awaken readers to the impressive need in these countries. Several
services like Doctors Without Borders and Samaritan’s Purse work to fight these
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infections in developing countries. However, local hospitals and mission hospitals
continually need supplies like gloves, gowns and cleaning supplies to curb the spread of
infection. Donations to organizations like this can help to fight antibiotic resistance.
Additionally, organizations like Samaritan’s Purse and Doctors Without Borders
have a great need for committed workers that will work as healthcare professionals,
office workers, administrators and scientists. To defeat the threat of infection more
people will need to commit to the task. Furthermore, more time and money will need to
be spent in labs working on viable testing methods for antibiotic resistance and infection
diagnostics. Currently, rural and impoverished areas rely heavily on “dipstick” tests that
can quickly test for the presence of an infection like C. difficile by using a patient’s
blood. While these tools can often be lifesaving by properly diagnosing a condition like a
CDI before it causes sepsis and death, the tests are not always accurate. False positives or
negatives can affect the course of treatment and lead to prolonged sickness or even
fatalities. Even if the diagnosis is correct, these tests of the dipstick variety cannot replace
lab tests in that they will be unable to determine if the bacteria present is a resistant strain
or not. It will only be through diligence in the lab and on the field, that antibiotic
resistance can be conquered in impoverished areas.
Finally, one purpose of this thesis has been to explain ways that exist already to
prevent and treat antibiotic resistant infections. Hygiene and sanitation within healthcare
settings is the major aspect of this. The good news about most antibiotic resistant
infections being nosocomial is that the trend of increasing infections and fatalities can be
reversed rather quickly with proper healthcare practices. Healthcare professionals need to
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take the utmost care in their vocations by using gloves, proper handwashing techniques,
effective sanitation and scrubs when needed to ensure that no infections will spread via
the healthcare faculty. Just because a healthy doctor or nurse is not susceptible to a
MRSA infection or CDI does not mean that the myriads of other immunocompromised
and antibiotic treated patients are not.
For people who are developing symptoms associated with infections, it is
important that proper sanitation measures are taken to prevent spreading the infection to
others that the person may come in contact with. Per the CDC, bleach should be used to
thoroughly clean bathrooms of infected persons if they have recently been treated at a
hospital, been on antibiotics or visited a low-income area [36]. Bleach is often the only
feasible way to kill endospores such as those produced by C. difficile that can remain on
surfaces for days. Adequately cleaning and disinfecting can help to keep others healthy
when one person is sick with a resistant infection.
At the core of this thesis is the notion that antibiotic resistance is not a thing that
is unbeatable. There are no such things as “super bugs” that are completely resistant to
every antibiotic in existence. The reality is that certain factors have driven antibiotic
resistance to new heights. Broad-spectrum antibiotics like tetracyclines and ciproflaxin
are not as effective in extinguishing certain ailments as their ancestor drugs were fifty
years ago. Mutations have provided avenues for small pockets of bacteria to persist even
through the harshest treatments with broad-spectrum antibiotics. This is not to say these
antibiotics are useless; they are far from it and continue to save lives. But, it is time for
medicine to adapt to the adaptations that bacterial infections have made. Pathogens are
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adaptable and medical science must continue to be diligent to beat them. This has been
the narrative since the dawn of the empirical age.
Vaccines have saved millions of lives since their inception. Yet, vaccines like the
influenza immunization continually need to be made to adapt to the changing viral
strains. Similarly, the advent of penicillin has saved millions of lives as well, but as
bacteria that are affected less by the broad-spectrum penicillin-derivatives continue to
multiply, broad-spectrum treatments such as carbopenems, ciproflaxin, doxycycline, and
streptomycin should not be reverted to in a knee-jerk fashion. Testing methods must
improve so that their costs will cheapen, and even hospitals in impoverished areas can
one day afford to test the susceptibilities of bacterial strains against different antibiotics
and receive the results within one day. Narrow-spectrum antibiotics need to be prescribed
in synergy with broad-spectrum ones to completely inactivate infections. The only way to
beat antimicrobial resistant infections, and to give developing countries a chance against
them, is to make a concerted effort to increase the quality and lower the cost of
prevention and care. It surely will take effort, but medical tasks just as hefty have been
completed before.
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